

## Disclosures

### Personal Commercial (12)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Accelaron/Merck	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Aerovate	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Aerovate	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Gossamer	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Janssen Pharmaceuticals, Inc (Actelion)	Other - Consultant	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Jucabio	Consultant Fees/Honoraria	None (\$0)	Pulmonary Hypertension and Venous Thromboembolic
Keros	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Keros	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Medtronic	Consultant Fees/Honoraria	None (\$0)	Pulmonary Hypertension and Venous Thromboembolic
United Therapeutics	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
<i>Spouse/Domestic Partner/Immediate Household Member</i>			
Intellia- former employee end July 2024	Ownership Interest/Partnership/Principal	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Pathos	Salary	Significant (>= \$5,000)	Other

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Altavant	Research/Research Grants	None (\$0)	Pulmonary Hypertension and Venous Thromboembolic
Bayer	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 2/5/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 2/5/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 2/5/2025

---

**ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.